Date: 2011-07-19
Type of information: Development agreement
Compound: novel drug candidates
Company: to-BBB (The Netherlands) Emultech (The Netherlands)
Therapeutic area: CNS diseases
Type agreement: development
Action mechanism:
Disease: undisclosed untreated CNS diseases
Details: The drug delivery development company EmulTech and the brain drug delivery company to-BBB have announced a collaborative partnership. The two companies will combine their proprietary platforms to develop innovative medicines for untreated CNS diseases.
EmulTech will use its micro particle technology, called Emulsion Technology for Micro Encapsulates (ET4ME). Starting with small-scale feasibility studies, EmulTech is able to quickly test various formulations, requiring only small volumes. Its parallel scale up strategy allows for swift and reproducible scale up.
Based on its proprietary G-Technology®, to-BBB is developing brain-targeted liposomes. These liposomes are coated with the endogenous antioxidant glutathione at the tips of polyethylene glycol(PEG) to safely enhance the delivery to the brain. The company is applying the G-Technology® for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101.
Financial terms:
Latest news:
